Stocks / NASDAQ / Palvella Therapeutics Inc.

Palvella Therapeutics Inc.

Industry: Health Care – Biotechnology: Pharmaceutical Preparations

Stock Symbol: PVLA – NASDAQ

Animal Usage: Animal Testing

Our Opinion

Palvella Therapeutics Inc. is on the Cruelty Free Investing use of animals list because they conduct pre-clinical studies of their drugs on animals to assess a product’s safety profile.

Supporting Evidence:

The company confirms in corporate disclosures that it utilizes animal subjects for product testing.

“Foundational research at Yale University and Columbia University has identified mTOR as a key driver of BCC tumorigenesis in GS, and preclinical studies demonstrated that rapamycin significantly reduced total BCC tumor burden when compared to vehicle treatment in a mouse model that closely mimics the accelerated BCC growth pattern of patients with GS;5 targeting inhibition of mTOR may overcome limitations associated with smoothened inhibitors which have been documented to be associated with clinical resistance and substantial tumor recurrence.” Read the article for more details

Company Description

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company’s lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.

Company Website: https://www.palvellatx.com

Contact: info@palvellatx.com